Z-VDVAD-FMK is a special inhibitor of caspase-2 . Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis In Vitro Cotreatment of cells with the caspase inhibitors Ac-DEVD-CHO, Z-VDVAD-FMK (100 μM), Z-IETD-fmk, and Z-LEHD-fmk alone or in combination, or overexpression of CrmA, prevents many morphological features of apoptosis but not loss of mitochondrial membrane potential (DCm), phospatidilserine exposure, and cell death. Z-VDVAD-FMK (2 μM) greatly inhibits the Rho-kinase activity in HMEC-1 cells stimulated by Thrombin and displays no effect on control cells. Z-VDVAD-FMK (zVDVAD-fmk) produces a reduction in Lovastatin-induced apoptosis. Z-VDVAD-FMK (100 μM) significantly reduces Lovastatin-induced loss of DNA by 19.1±8.3%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: The human T-cell leukemia Jurkat (Clone E6.1, ATCC TIB-152) Concentration: 100 μM Incubation Time: 22 hours Result: Prevented Doxorubicin (1 μM)-induced nuclear apoptosis, but not cell death. Form:Solid IC50& Target:Caspase-2